Bryostatin-1

Neurotrope Inc (NASDAQ: NTRP) announced “positive topline results” for its leading Alzheimer's drug in a press release, but investors weren’t fooled. “The study failed,” Adam Feuerstein, biotech reporter at TheStreet, said Monday on Benzinga’s PreMarket Prep...